Brian Piekos - 01 Jun 2023 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: ELTX
Reported as of: 01 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2023, 17:25:16 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 05 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Nishant M. Dharia, Attorney-in-fact

Key filing fact

Brian Piekos filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 05 Jun 2023.

Key facts

This page summarizes Brian Piekos's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2023, 17:25.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +75,484
Change %
Price: $0.000000
Shares after: 75,484
Date: 01 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,484
Exercise price: $10.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 25% of the option shares on May 15, 2024 with the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to the Reporting Person continuing to provide services to the Issuer through the applicable vesting dates, and provided that in the event there is a change in control of the Issuer, followed by a subsequent termination of the Reporting Person's employment without cause (or a material diminishment of his role) within 12 months of the change of control, any unvested options granted will immediately vest.